posted
GenoMed, Inc. (Pink Sheets:GMED): is a Next Generation DMtm company that uses medical genomics to improve patient outcomes. GenoMed is working to translate knowledge of medical genomics--the study of which genes cause disease--into clinical practice. We combine biotechnology with Disease Management (DM). We develop new and better drugs, we use existing drugs for new disease indications, and we uncover disease before symptoms arise. By studying disease genes, we hope to make medicine more proactive and disease prevention more effective. Website:http://www.genomedics.comPosts: 1113 | Registered: Jun 2005
| IP: Logged |
posted
GenoMed CEO Honored for Innovation in Healthcare by St. Louis Business Journal
Contact: David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz*genomed.com
ST. LOUIS--October 25, 2005--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health, announced today that its CEO, David W. Moskowitz MD, has been nominated as a finalist in the 2005 Health Care Heroes sponsored by the St. Louis Business Journal.
Now in its second year, the Health Care Heroes of St. Louis is an annual celebration organized by the St. Louis Business Journal to tell the stories of those who have benefited from the innovation and dedication of heroes in the health care profession. The event will be held November 10, 2005 in St. Louis (http://stlouis.bizjournals.com/stlouis/event/1916).
GenoMed currently earns revenues from its published protocols to reverse chronic kidney failure due to diabetes or high blood pressure, and delay progression of emphysema. These diseases affect 90 million Americans. The Company is currently conducting free trials for many additional diseases, including Parkinson's disease, Alzheimer's disease, most cancers, and viral diseases including West Nile virus encephalitis, regular influenza, and avian influenza.
Any one interested in signing up for GenoMed's trial just needs to go to GenoMed's website (www.genomed.com), and follow the links for the "Flu trial." The trial documents are self-explanatory.
About GenoMed
GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975). .
Posts: 1113 | Registered: Jun 2005
| IP: Logged |
posted
Dave Moskowitz is a stand up guy. Been involved with this company for nearly 2 years. Nice little pinkie to keep in your basket for the future, IMO.
Posts: 108 | Registered: Apr 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
